Daflon for Chronic Venous Insufficiency Treatment

Role in CVI Treatment Algorithm

• Compression therapy remains the mandatory first-line conservative treatment for CVI, with Daflon serving as an adjunctive pharmacological option to enhance symptom control, as recommended by the American College of Phlebology 1
• For advanced disease, Daflon is appropriate as adjunctive therapy to compression, but interventional treatment should not be delayed for prolonged pharmacological trials, according to the American College of Phlebology 1

Critical Treatment Considerations

• The American College of Phlebology recommends that Daflon should not replace compression therapy, which remains mandatory for CVI treatment 1
• For CEAP C4-C6 disease with significant reflux, interventional treatment should not be delayed for prolonged pharmacological trials with Daflon, as stated by the American College of Phlebology 1
• Daflon does not address the underlying anatomical problem of saphenofemoral or saphenopopliteal junction reflux that requires definitive treatment, as noted by the American College of Phlebology 1 and the Society for Vascular Surgery 2

Comparison to Other Venoactive Drugs

• The American Heart Association found low-quality evidence for venoactive drugs with high inconsistency and imprecision, highlighting the need for further research 3
• The World Journal of Emergency Surgery noted that while other phlebotonics showed benefits for pruritus, bleeding, and overall symptom improvement in hemorrhoidal disease, the evidence quality limits strong recommendations for acute care settings, as stated by the American Society of Colon and Rectal Surgeons 4